Back to Agenda
Strategy for Early-stage Research and Development of siRNA and ADCs
Session Chair(s)
Bei HU
Professor of Clinical Pharmacology, Clinical Pharmacology Research Centre
Peking Union Medical College Hospital, China
From small molecules to macromolecules, from cell therapy to gene therapy, domestic research and development of innovative drugs has emerged in an endless stream. Small interfering RNA (siRNA) therapy is one of the most important breakthroughs in the field of drug research and development in the past more than a decade. It is widely believed that, this therapy will probably bring revolutionary changes to the pharmaceutical field in the next decade, and promote the formation of the third development wave of modern pharmaceuticals after small molecular drugs and antibody drugs. With the constant development of gene sequencing technology, the selection of target is clearer, providing a bigger space for the great improvement in the safety and efficacy of siRNA drugs. Meanwhile, breakthrough progresses have been made constantly in the research and development of antibody biological drugs. Antibody– drug conjugates (ADCs) have gradually become a new trend of research and development on anti-tumor drugs. Same as the other drugs, clinical early research is a bottle-neck in the research and development of siRNA and ADCs drugs, and it relates to the overall strategic decision on drug research and development. This session will invite top-ranking experts on development of siRNA and ADCs drugs to share the information on the future research & development trend of the two types of drugs, as well as the strategy for early clinical research and development of such drugs.
Have an account?